Celgene exercises early option to exclusively license GI-6207, novel cancer immunotherapy
GlobeImmune announced that Celgene exercised its option under the 2009 Collaboration and Option Agreement to exclusively license GI-6207, a Tarmogen® product candidate targeting cancers that express carcinoembryonic antigen. GlobeImmune will receive an option exercise payment of $1.9 million. August 04, 2015